CIBC Private Wealth Group LLC lifted its stake in shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) by 42.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 114,160 shares of the biotechnology company’s stock after purchasing an additional 34,160 shares during the quarter. CIBC Private Wealth Group LLC owned about 0.12% of Arrowhead Pharmaceuticals worth $1,417,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of ARWR. Bank of America Corp DE raised its position in Arrowhead Pharmaceuticals by 339.8% in the second quarter. Bank of America Corp DE now owns 73,657 shares of the biotechnology company’s stock worth $1,002,000 after acquiring an additional 56,909 shares in the last quarter. Bailard Inc. raised its position in Arrowhead Pharmaceuticals by 214.3% in the fourth quarter. Bailard Inc. now owns 110,000 shares of the biotechnology company’s stock worth $1,366,000 after acquiring an additional 75,000 shares in the last quarter. Northern Trust Corp raised its position in Arrowhead Pharmaceuticals by 380.1% in the second quarter. Northern Trust Corp now owns 1,063,499 shares of the biotechnology company’s stock worth $14,464,000 after acquiring an additional 841,982 shares in the last quarter. Candriam Luxembourg S.C.A. bought a new stake in Arrowhead Pharmaceuticals in the third quarter worth about $9,853,000. Finally, Credit Suisse AG raised its position in Arrowhead Pharmaceuticals by 15.1% in the third quarter. Credit Suisse AG now owns 82,739 shares of the biotechnology company’s stock worth $1,586,000 after acquiring an additional 10,843 shares in the last quarter. Institutional investors and hedge funds own 59.52% of the company’s stock.

NASDAQ ARWR opened at $17.92 on Tuesday. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -27.57 and a beta of 2.23. Arrowhead Pharmaceuticals Inc has a 1 year low of $5.35 and a 1 year high of $22.39.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, February 7th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.76 by ($0.63). The company had revenue of $34.66 million for the quarter, compared to analyst estimates of $90.88 million. Arrowhead Pharmaceuticals had a negative return on equity of 24.23% and a negative net margin of 61.78%. Equities analysts expect that Arrowhead Pharmaceuticals Inc will post 1.21 earnings per share for the current year.

In other Arrowhead Pharmaceuticals news, Director Douglas B. Given sold 3,000 shares of the business’s stock in a transaction dated Friday, November 23rd. The stock was sold at an average price of $12.74, for a total transaction of $38,220.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Bruce D. Given sold 242,834 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, February 12th. The shares were sold at an average price of $16.04, for a total value of $3,895,057.36. Following the transaction, the chief operating officer now directly owns 859,523 shares in the company, valued at approximately $13,786,748.92. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 972,375 shares of company stock worth $14,143,250. Corporate insiders own 4.80% of the company’s stock.

Several equities research analysts have commented on ARWR shares. BidaskClub upgraded shares of Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, February 14th. Chardan Capital reiterated a “buy” rating and issued a $24.50 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, February 11th. Finally, Cantor Fitzgerald set a $24.00 price target on shares of Arrowhead Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 11th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $21.36.

ILLEGAL ACTIVITY WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/arrowhead-pharmaceuticals-inc-arwr-position-raised-by-cibc-private-wealth-group-llc/2831819.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company offers ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver disease related to alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

Recommended Story: Understanding each part of a balance sheet

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.